Cargando…

Changes in Glucose Intolerance after Treatment with Antithyroid Drugs in Patients with Graves' Disease Using Continuous Glucose Monitoring: A Pilot Study

OBJECTIVE: Graves' disease (GD) is known to cause glucose intolerance. The present study used continuous glucose monitoring (CGM) in 15 patients newly diagnosed with GD to evaluate changes in glucose trends following improvement in the thyroid function. METHODS: At the time of the diagnosis of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kurozumi, Akira, Okada, Yosuke, Tanaka, Yoshiya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208777/ https://www.ncbi.nlm.nih.gov/pubmed/36171124 http://dx.doi.org/10.2169/internalmedicine.0364-22

Ejemplares similares

Efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring
por: Kurozumi, Akira, et al.
Publicado: (2013)

Hypoglycemia in blood glucose level in type 2 diabetic Japanese patients by continuous glucose monitoring
por: Hajime, Maiko, et al.
Publicado: (2019)

Relationship between interstitial glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics; a pilot study
por: Tokutsu, Akemi, et al.
Publicado: (2020)

Twenty‐four‐hour variations in blood glucose level in Japanese type 2 diabetes patients based on continuous glucose monitoring
por: Hajime, Maiko, et al.
Publicado: (2017)

Antithyroid Drug Treatment in Graves’ Disease
por: Chung, Jae Hoon
Publicado: (2021)

Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus
por: Torimoto, Keiichi, et al.
Publicado: (2013)

Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring
por: Torimoto, Keiichi, et al.
Publicado: (2017)

Relationship between glycemic intraday variations evaluated in continuous glucose monitoring and HbA1c variability in type 2 diabetes: pilot study
por: Tokutsu, Akemi, et al.
Publicado: (2021)

Changes in the Ocular Parameters of Patients with Graves’ Disease after Antithyroid Drug Treatment
por: Lee, Je-Sang, et al.
Publicado: (2021)

Antithyroid Drug Therapy for Graves' Disease and Implications for Recurrence
por: Liu, Jia, et al.
Publicado: (2017)

Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring
por: Uemura, Fumi, et al.
Publicado: (2021)

Comprehensive immunophenotypic analysis reveals the pathological involvement of Th17 cells in Graves' disease
por: Torimoto, Keiichi, et al.
Publicado: (2022)

Antithyroid drugs in Graves’ disease: Are we stretching it too far?
por: Jayaraman, Muthukrishnan, et al.
Publicado: (2016)

Antithyroid Drugs in the Management of Graves' Disease: A Friend and Foe
por: Butt, Muhammad I, et al.
Publicado: (2023)

Prediction for recurrence following antithyroid drug therapy for Graves’ hyperthyroidism
por: Weng, Huan, et al.
Publicado: (2023)

Determinants of hemoglobin A1c level in patients with type 2 diabetes after in‐hospital diabetes education: A study based on continuous glucose monitoring
por: Torimoto, Keiichi, et al.
Publicado: (2016)

Indefinite antithyroid drug therapy in toxic Graves’ disease: What are the cons
por: Rajput, Rajesh, et al.
Publicado: (2013)

Risk Factors for Granulocytopenia in Patients with Graves' Disease Receiving Antithyroid Drugs
por: Li, Jiaxi, et al.
Publicado: (2023)

The thyroid function of Graves' disease patients is aggravated by depressive personality during antithyroid drug treatment
por: Fukao, Atsushi, et al.
Publicado: (2011)

Glycemic variation in uncontrolled Graves’ disease patients with normal glucose metabolism: Assessment by continuous glucose monitoring
por: Gao, Gu, et al.
Publicado: (2018)

Early Biochemical Response to Antithyroid Drugs in Graves’ Disease: The Role of Initial Dosing
por: El Kawkgi, Omar M, et al.
Publicado: (2021)

Clinical Features and Remission Rate of Pediatric Graves’ Hyperthyroidism Treated With Antithyroid Drug
por: You, Kyusang, et al.
Publicado: (2021)

Long-term outcomes of Graves’ disease in children and adolescents receiving antithyroid drugs
por: Rho, Jung Gi, et al.
Publicado: (2021)

Associations between continuous glucose monitoring-derived metrics and diabetic retinopathy and albuminuria in patients with type 2 diabetes
por: Wakasugi, Satomi, et al.
Publicado: (2021)

Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy
por: Choi, Yun Mi, et al.
Publicado: (2019)

The Importance of Continuous Glucose Monitoring-derived Metrics Beyond HbA1c for Optimal Individualized Glycemic Control
por: Yoshii, Hidenori, et al.
Publicado: (2022)

Predictive Value of Gene Polymorphisms on Recurrence after the Withdrawal of Antithyroid Drugs in Patients with Graves’ Disease
por: Liu, Jia, et al.
Publicado: (2017)

Antithyroid drugs
por: Jastrzębska, Helena
Publicado: (2015)

Antithyroid Drugs
por: Abdi, Hengameh, et al.
Publicado: (2019)

Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves' disease?
por: Belsing, Tina Z, et al.
Publicado: (2010)

Relationship between dose of antithyroid drugs and adverse events in pediatric patients with Graves’ disease
por: Yasuda, Kie, et al.
Publicado: (2017)

Commentary on "Long-term outcomes of Graves’ disease in children and adolescents receiving antithyroid drugs"
por: Kim, Minsun
Publicado: (2021)

Remission in pediatric Graves’ disease treated with antithyroid drug and the risk factors associated with relapse
por: Wong, Tsz Wai Catherine, et al.
Publicado: (2022)

Targeting glucose control in preterm infants: pilot studies of continuous glucose monitoring
por: Thomson, Lynn, et al.
Publicado: (2019)

Excess Visceral Adipose Tissue Worsens the Vascular Endothelial Function in Patients with Type 2 Diabetes Mellitus
por: Kurozumi, Akira, et al.
Publicado: (2016)

Case of autoimmune polyendocrine syndrome type 3 complicated with anti‐N‐methyl‐D‐aspartic acid‐receptor encephalitis
por: Kurozumi, Akira, et al.
Publicado: (2020)

A Comparative Study on the Efficacy and Safety of Dose Escalation of Luseogliflozin in Type 2 Diabetes Mellitus Patients With Poor Glycemic Control
por: Arao, Tadashi, et al.
Publicado: (2023)

A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice
por: Liu, Xiaomei, et al.
Publicado: (2015)

Predictors of Initial and Sustained Remission in Patients Treated with Antithyroid Drugs for Graves' Hyperthyroidism: The RISG Study
por: Karmisholt, J., et al.
Publicado: (2019)

Commentary on “Remission in pediatric Graves’ disease treated with antithyroid drug and the risk factors associated with relapse”
por: Kim, Ji Hyun
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t36dvt9lao6avoi1302rit31f0